XML 12 R4.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Operating expenses:        
Research and development $ 2,858 $ 2,493 $ 8,394 $ 6,896
General and administrative 2,397 1,998 6,813 6,167
Total operating expenses 5,255 4,491 15,207 13,063
Loss from operations (3,799) (3,251) (10,795) (9,463)
Other income (expense):        
Financing expense     (3,545)  
Change in fair value of warrants 960   5,654  
Warrant issuance costs (54)   (486)  
Interest income 80 119 219 290
Interest expense (61) (87) (122) (333)
Total other income (expense) 925 32 1,720 (43)
Net loss $ (2,874) $ (3,219) $ (9,075) $ (9,506)
Per share information:        
Net loss per share of common stock - basic $ (0.37) $ (1) $ (1.46) $ (3.54)
Weighted average number of shares of common stock outstanding - basic 7,855,763 3,225,351 6,232,123 2,688,232
Net loss per share of common stock - diluted $ (0.37) $ (1) $ (1.67) $ (3.54)
Weighted average number of shares of common stock outstanding - diluted 7,855,763 3,225,351 8,452,338 2,688,232
Grant [Member]        
Revenue $ 1,456 $ 1,240 $ 4,412 $ 3,600